208 related articles for article (PubMed ID: 27621419)
1. Epstein-Barr viral miRNAs inhibit antiviral CD4+ T cell responses targeting IL-12 and peptide processing.
Tagawa T; Albanese M; Bouvet M; Moosmann A; Mautner J; Heissmeyer V; Zielinski C; Lutter D; Hoser J; Hastreiter M; Hayes M; Sugden B; Hammerschmidt W
J Exp Med; 2016 Sep; 213(10):2065-80. PubMed ID: 27621419
[TBL] [Abstract][Full Text] [Related]
2. Epstein-Barr virus microRNAs reduce immune surveillance by virus-specific CD8+ T cells.
Albanese M; Tagawa T; Bouvet M; Maliqi L; Lutter D; Hoser J; Hastreiter M; Hayes M; Sugden B; Martin L; Moosmann A; Hammerschmidt W
Proc Natl Acad Sci U S A; 2016 Oct; 113(42):E6467-E6475. PubMed ID: 27698133
[TBL] [Abstract][Full Text] [Related]
3. An Epstein-Barr Virus MicroRNA Blocks Interleukin-1 (IL-1) Signaling by Targeting IL-1 Receptor 1.
Skinner CM; Ivanov NS; Barr SA; Chen Y; Skalsky RL
J Virol; 2017 Nov; 91(21):. PubMed ID: 28794034
[TBL] [Abstract][Full Text] [Related]
4. Epstein-Barr virus evasion of CD8(+) and CD4(+) T cell immunity via concerted actions of multiple gene products.
Ressing ME; Horst D; Griffin BD; Tellam J; Zuo J; Khanna R; Rowe M; Wiertz EJ
Semin Cancer Biol; 2008 Dec; 18(6):397-408. PubMed ID: 18977445
[TBL] [Abstract][Full Text] [Related]
5. The EBV immunoevasins vIL-10 and BNLF2a protect newly infected B cells from immune recognition and elimination.
Jochum S; Moosmann A; Lang S; Hammerschmidt W; Zeidler R
PLoS Pathog; 2012; 8(5):e1002704. PubMed ID: 22615564
[TBL] [Abstract][Full Text] [Related]
6. Functional analysis of the CD4(+) T-cell response to Epstein-Barr virus: T-cell-mediated activation of resting B cells and induction of viral BZLF1 expression.
Fu Z; Cannon MJ
J Virol; 2000 Jul; 74(14):6675-9. PubMed ID: 10864684
[TBL] [Abstract][Full Text] [Related]
7. CD4+ T-cell effectors inhibit Epstein-Barr virus-induced B-cell proliferation.
Nikiforow S; Bottomly K; Miller G
J Virol; 2001 Apr; 75(8):3740-52. PubMed ID: 11264363
[TBL] [Abstract][Full Text] [Related]
8. Primary CD4+ T-cell responses provide both helper and cytotoxic functions during Epstein-Barr virus infection and transformation of fetal cord blood B cells.
MacArthur GJ; Wilson AD; Birchall MA; Morgan AJ
J Virol; 2007 May; 81(9):4766-75. PubMed ID: 17314172
[TBL] [Abstract][Full Text] [Related]
9. Human B cells on their route to latent infection--early but transient expression of lytic genes of Epstein-Barr virus.
Kalla M; Hammerschmidt W
Eur J Cell Biol; 2012 Jan; 91(1):65-9. PubMed ID: 21450364
[TBL] [Abstract][Full Text] [Related]
10. An update: Epstein-Barr virus and immune evasion via microRNA regulation.
Zuo L; Yue W; Du S; Xin S; Zhang J; Liu L; Li G; Lu J
Virol Sin; 2017 Jun; 32(3):175-187. PubMed ID: 28669004
[TBL] [Abstract][Full Text] [Related]
11. MYC overexpression imposes a nonimmunogenic phenotype on Epstein-Barr virus-infected B cells.
Staege MS; Lee SP; Frisan T; Mautner J; Scholz S; Pajic A; Rickinson AB; Masucci MG; Polack A; Bornkamm GW
Proc Natl Acad Sci U S A; 2002 Apr; 99(7):4550-5. PubMed ID: 11917131
[TBL] [Abstract][Full Text] [Related]
12. Measurement of CD8+ and CD4+ T Cell Frequencies Specific for EBV LMP1 and LMP2a Using mRNA-Transfected DCs.
Sohn DH; Sohn HJ; Lee HJ; Lee SD; Kim S; Hyun SJ; Cho HI; Cho SG; Lee SK; Kim TG
PLoS One; 2015; 10(5):e0127899. PubMed ID: 26023769
[TBL] [Abstract][Full Text] [Related]
13. Innate Immune Recognition of EBV.
Lünemann A; Rowe M; Nadal D
Curr Top Microbiol Immunol; 2015; 391():265-87. PubMed ID: 26428378
[TBL] [Abstract][Full Text] [Related]
14. CD4(+) T-cell responses to Epstein-Barr virus (EBV) latent membrane protein 1 in infectious mononucleosis and EBV-associated non-Hodgkin lymphoma: Th1 in active disease but Tr1 in remission.
Marshall NA; Culligan DJ; Johnston PW; Millar C; Barker RN; Vickers MA
Br J Haematol; 2007 Oct; 139(1):81-9. PubMed ID: 17854310
[TBL] [Abstract][Full Text] [Related]
15. Immune Evasion by Epstein-Barr Virus.
Ressing ME; van Gent M; Gram AM; Hooykaas MJ; Piersma SJ; Wiertz EJ
Curr Top Microbiol Immunol; 2015; 391():355-81. PubMed ID: 26428381
[TBL] [Abstract][Full Text] [Related]
16. Evaluation of suitable target antigens and immunoassays for high-accuracy immune monitoring of cytomegalovirus and Epstein-Barr virus-specific T cells as targets of interest in immunotherapeutic approaches.
Tischer S; Dieks D; Sukdolak C; Bunse C; Figueiredo C; Immenschuh S; Borchers S; Stripecke R; Maecker-Kolhoff B; Blasczyk R; Eiz-Vesper B
J Immunol Methods; 2014 Jun; 408():101-13. PubMed ID: 24877879
[TBL] [Abstract][Full Text] [Related]
17. EBV Latency II-derived peptides induce a specific CD4+ cytotoxic T-cell activity and not a CD4+ regulatory T-cell response.
Moralès O; Depil S; Mrizak D; Martin N; Ndour PA; Dufosse F; Miroux C; Coll J; de Launoit Y; Auriault C; Pancre V; Delhem N
J Immunother; 2012 Apr; 35(3):254-66. PubMed ID: 22421943
[TBL] [Abstract][Full Text] [Related]
18. Specificity of T cells in synovial fluid: high frequencies of CD8(+) T cells that are specific for certain viral epitopes.
Tan LC; Mowat AG; Fazou C; Rostron T; Roskell H; Dunbar PR; Tournay C; Romagné F; Peyrat MA; Houssaint E; Bonneville M; Rickinson AB; McMichael AJ; Callan MF
Arthritis Res; 2000; 2(2):154-64. PubMed ID: 11062606
[TBL] [Abstract][Full Text] [Related]
19. EBV-encoded miRNAs.
Barth S; Meister G; Grässer FA
Biochim Biophys Acta; 2011; 1809(11-12):631-40. PubMed ID: 21640213
[TBL] [Abstract][Full Text] [Related]
20. EBNA1-specific CD4+ T cells in healthy carriers of Epstein-Barr virus are primarily Th1 in function.
Bickham K; Münz C; Tsang ML; Larsson M; Fonteneau JF; Bhardwaj N; Steinman R
J Clin Invest; 2001 Jan; 107(1):121-30. PubMed ID: 11134187
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
